FDA shared a post on LinkedIn:
“A drug that treats an ultra-rare, aggressive cancer that forms in the bile ducts, zenocutuzumab-zbco, has been granted the 22nd voucher under the FDA’s Commissioner’s National Priority Voucher pilot program.
Announced in June 2025, the CNPV seeks to expedite approval of applications that address critical national health priorities, such as bringing innovative therapies to the American people, addressing large unmet medical needs, promoting domestic manufacturing, and increasing affordability. A company selected for the program is issued a voucher entitling the company to benefits including enhanced communications and rolling review to allow for a shortened review time.”
Other articles about FDA on OncoDaily